Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**11C-CGP 12177** is a radiolabeled ligand used primarily as a positron emission tomography (PET) tracer for the in vivo quantification of beta-adrenoceptors (beta-adrenergic receptors), especially in cardiac tissue. It is the carbon-11 labeled form of CGP 12177, which itself is a high-affinity antagonist at beta1 and beta2 adrenoceptors and acts as a partial agonist at beta3 adrenoceptors. The compound enables noninvasive measurement of myocardial beta-adrenoceptor density and has been used to assess receptor changes in conditions such as heart failure and idiopathic cardiomyopathy[1][2][7]. Its mechanism involves binding to G-protein coupled beta-adrenoceptors on cell membranes in tissues like heart muscle, adipose tissue, and vascular smooth muscle[6]. The radiotracer is synthesized with high specific activity for intravenous injection and clinical PET imaging applications[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 11C-CGP 12177.